Contact Us
Drug Search Results
More Filters [+]

Clevudine

Alternative Names: clevudine
Latest Update: 2024-04-08
Latest Update Note: PubMed Publication

Product Description

or the treatment of chronic hepatitis B (HBV) infection. (Sourced from: https://www.sec.gov/Archives/edgar/data/1301081/000119312509084603/dex991.htm)

Mechanisms of Action: Viral Replication Inhibitor,DNA Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Korea | Philippines | Thailand

Approved Indications: None

Known Adverse Events: None

Company: Bukwang
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Clevudine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hepatitis B|Hepatitis B, Chronic|Hepatitis A|Hepatocellular Carcinoma

Phase 3: Hepatitis B, Chronic|Hepatitis B|Hepatitis A|Other|Hepatitis D, Chronic

Phase 2: COVID-19|Hepatitis B|Hepatitis A|Hepatitis B, Chronic

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
1B-11-9

N/A

Terminated

Breast Cancer

2022-11-01

BK-CLV-203

P2

Completed

COVID-19

2021-07-05

25%
BK-CLV-201

P2

Completed

COVID-19

2021-02-24

25%
CLV-408

P4

Terminated

Hepatitis A|Hepatitis B, Chronic

2014-11-01

Recent News Events

Date

Type

Title

04/08/2024

PubMed

 DFT/TDDFT calculations of geometry optimization, electronic structure and spectral properties of clevudine and telbivudine for treatment of chronic hepatitis B.

11/23/2022

PubMed

 Protecting-group-free synthesis of clevudine (L-FMAU), a treatment of the hepatitis B virus.

06/25/2022

News Article

 Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study

06/08/2022

News Article

 Antios Therapeutics Announces Oral Presentations on ATI-2173, ATI-1428, and ATI-1645 Hepatitis B Virus Programs at the EASL International Liver Congress™ 2022

04/26/2022

News Article

 Antios Therapeutics Announces Notice of Allowance for U.S. Patent on Phosphoramidates for the Treatment of Hepatitis B Virus

03/30/2022

News Article

 Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions